Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Saturday that a phase 4 trial of Dupixent in adults and adolescents showed improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.

At 24 weeks, 76% of patients achieved an improvement rate of at least 75% in overall disease severity, while 53% achieved clinically meaningful improvement in itch.

Patients experienced a 53% cut from baseline in post-inflammatory hyperpigmentation, the companies said.

Atopic dermatitis is a disease that disproportionately impacts communities of color.